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1. Introduction
Diabetes mellitus is a group of disorders of multiple aetiologies resulting from a defect in
insulin secretion, insulin action, or both. Insulin deficiency in turn leads to chronic hypergly‐
cemia (very high blood glucose levels) with disturbances in carbohydrate, fat and protein
metabolism [1]. The two major types of diabetes mellitus (DM) are insulin dependent (IDDM)
- type 1 and non -insulin dependent (NIDDM) -type 2. Type 1 DM is characterized by a specific
destruction of the pancreatic β cells commonly associated with immune-mediated damage [2].
Individuals with type 2 DM display a gradual change in glucose homeostasis due to insulin
resistance and/or decreased insulin secretion [3].
Sustained hyperglycemia leads to the progressive development of long-term microvascular
and macrovascular complications which causes morbidity and mortality among those affected
[4, 5]. Although glycemic control has long been the mainstay for preventing the progression
of diabetic complications, there is far less evidence that these interventions reverse diabetic
complications [6]. Also, limitations in intensive glycemic treatment such as difficulty in
achieving and/or maintaining tight glycemic control [7], incidence of hypoglycemia and
increased mortality [8, 9] suggest an urgent need for alternative and/or complementary
therapies to this disorder.
Hyperglycemia-induced oxidative stress is now recognized as the driving force for the
development of diabetic complications [10]. Oxidative stress in diabetes results in stimulation
of the polyol pathway, formation of advanced glycation end products (AGE), activation of
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protein kinase C (PKC) and subsequent formation of reactive oxygen radicals [11, 12].
Hyperglycemia, not only generates more reactive oxygen species (ROS), but also attenuates
antioxidative mechanisms by scavenging enzymes and substances [13].
2. The complications of diabetes mellitus (DM)
The injurious effects of hyperglycemia are separated into microvascular (involving small
vessels such as capillaries) and macrovascular complications (involving large vessels, such as
arteries and veins). Microvascular complications include diabetic nephropathy, neuropathy
and retinopathy while macrovascular complications include coronary artery disease, periph‐
eral arterial disease and stroke [5].
Diabetic nephropathy is a major cause of end-stage renal disease worldwide. It is a progressive
decline in the glomerular filtration rate, characterized by glomerular hyperfiltration, glomer‐
ular and tubular epithelial hypertrophy, increased urinary albumin excretion, increased
basement membrane thickness and mesangial expansion with the accumulation of extracel‐
lular matrix proteins (ECM) [14]. Alteration of the permeability characteristics of the glomer‐
ular capillary wall manifests clinically as abnormal albuminuria [15]. Microalbuminuria
progresses to end-stage renal disease through a number of stages including normoalbuminu‐
ria, microalbuminuria and macroalbuminuria [16].
Diabetic retinopathy results from the damage of the small vasculature of the retina, multi
cellular and the light sensitive tissue at the back of the eye. It is a major cause of visual
impairment worldwide [17, 18]. The retina capillaries are lined with endothelial cells respon‐
sible for maintaining the blood retinal barrier, and are surrounded by smooth muscle cells,
pericytes, which provide tone to the vessels [18]. The vascular lesions that are identified at the
early stage of diabetic retinopathy include pericytes disappearance from capillaries resulting
in pericyte ghosts, obliteration of capillaries and small arterioles, gradual thickening of
vascular basement membrane, increased permeability of endothelial cells, and formation of
microaneurysms (i.e. weakening of vessel walls that results in the projection of a balloonlike
sac), vessel leakage, exudate, and hemorrhage [19, 20].
Neuropathies are characterized by a progressive loss of nerve fiber function. A widely accepted
definition of diabetic neuropathy is “the presence of symptoms and/or signs of peripheral
nerve dysfunction in people with mellitus after exclusion of other causes” [21]. In the periph‐
eral nervous system, diabetes causes a progressive deterioration of sensory nerves and damage
to motor nerves [22]. Diabetic neuropathy is ultimately the leading cause of lower extremity
amputation [23]. Peripheral neuropathy is thought to develop because of cellular damage to
endothelial cells, affecting nerve blood flow and also damage to the neurons affecting con‐
ductivity of impulses [23]. Signs and symptoms of diabetic neuropathy include decrease or no
sweating, numbness, or tingling, and some sort of burning sensation, weakness and loss of
reflexes [24].
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Both type I and type II diabetes are powerful and independent risk factors for coronary artery
disease (CAD), stroke, and peripheral arterial disease [25, 26, 27]. Diabetics have a 2- to 4-fold
higher risk for cardiovascular events [28] and nearly 80% of diabetes-associated deaths are
caused by cardiovascular disease (CVD) [29]. Atherosclerosis, (excessive accumulation of
lipids, cholesterol, inflammatory cells, and connective tissue in the vessel wall) accounts for
more than 80% of the CVD-associated death and disability [30, 31]. Formation of atherosclerotic
plaques can result in occlusion of vessel lumen and a rapid cessation in blood flow to target
tissue [32]. Hyperglycemia, increased free fatty acids, and insulin resistance induce a large
number of alterations at the cellular level that contribute to vascular dysfunction and accelerate
the atherosclerotic process. These include increased oxidative stress, decreased bioavailability
of NO, disturbances of intracellular signal transduction and increased production of several
prothrombotic factors [32, 33].
3. Role of oxidative stress in diabetic complications
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are the terms collectively
describing free radicals and other non-radical reactive derivatives also called oxidants.
Biological free radicals are highly unstable molecules which are products of normal cellular
metabolism. They have electrons available to react with various organic substrates such as
lipids, proteins and deoxyribonucleic acid (DNA). Free radicals are well recognized for playing
a dual role as both deleterious and beneficial species, since they can be either harmful or
beneficial to living systems [34]. At low or moderate levels free radicals (ROS and RNS) exerts
beneficial effects such as defence against infectious agents, induction of a mitogenic response
and the maturation process of cellular structures [35-37]. ROS include superoxide anion
(O2 .-), hydroxyl (.OH), hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) while RNS
include nitric oxide (.NO), nitrogen dioxide (NO2 .-) and peroxynitrite (OONO−) [38, 39]. High
concentrations of free radicals on the other hand result in deleterious processes that can
damage cell structures due to oxidative stress [40, 41].
Free radicals produced under physiological conditions are maintained at steady state levels
by endogenous or exogenous antioxidants (externally supplied through foods or supple‐
ments)  which act  as  free radical  scavengers.  However,  oxidative stress  occurs when the
production of free radicals overwhelms the detoxification capacity of cellular antioxidant
system causing  biological  damage  [42-44].  The  endogenous  antioxidants  (Table  1)  com‐
prise  of  the  enzymatic  antioxidants  such  as  superoxide  dismutase  (SOD),  glutathione
peroxidase (GPx), glutathione reductase (GR), catalase (CAT), and non-enzymatic antioxi‐
dants including glutathione (GSH), α lipoic acid, vitamins C and E [39, 45, 46]. On the other
hand, the exogenous antioxidants include micronutrients and other exogenously adminis‐
tered compounds such as vitamin E, vitamin C, trace metals (selenium, manganese, zinc),
carotenoids and flavonoids [39, 44, 47].
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Antioxidants Cellular location Role Reference
Enzymatic Antioxidants
(A) Catalase Peroxisomes Decomposition of H2O2to water andoxygen [48]
(B) Glutathione peroxidase Cytoplasm, mitochondria,and nucleus
Detoxifies H2O2 and lipid peroxides with
simultaneous oxidation of GSH and
generation of GSSG
[49]
(C) Glutathione reductase Cytoplasm, mitochondria,and nucleus
Recycles Glutathione disulfide back to
glutathione using the cofactor NADPH [50]
(D) Superoxide dismutase Cytoplasm, nucleuslysosomes, mitochondria Conversion of superoxide radical to H2O2 [51]
Non enzymatic antioxidants
(A) GSH Cytoplasm, mitochondriaand nucleus
Acts as a cofactor for antioxidant
enzymes (GPx, GST), regenerates other
antioxidants such as Vitamins C and E to
their active forms
[52]
(B) Vitamin-E Membrane
Directly scavenge singlet oxygen, peroxyl
and superoxide radicals , protects
against peroxidation of membrane lipids
[34]
(C) Vitamin-C Cytosol
Acts synergistically with vitamin E to
terminate radical inducedlipid
peroxidation
[34, 53]
(D) α-Lipoic acid Cell membrane andcytoplasm
Increases glutathione and vitamin C
levels [54]
Table 1. Role of antioxidants in the protection against free radical damage
Numerous experimental evidences have highlighted a direct link between oxidative stress and
diabetes through the measurement of oxidative stress biomarkers in both diabetic patient and
rodents. As shown in Table 2, a hyperglycemic state can lead to an increase in the levels of
oxidative DNA damage markers such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) and 8-
oxo-7, 8-dihydro-2'-deoxyguanosine (8-oxodG); lipid-peroxidation products measured as
thiobarbituric acid-reactive substances (TBARS); protein oxidation products such as nitrotyr‐
osine and carbonyl levels and also lower the activity of antioxidant enzymes. Cell culture
studies using pancreatic beta cells, aortic smooth muscle cells and endothelial cells have also
provided evidence for an increase in ROS production in diabetes [55, 56].
Due to their ability to directly oxidize and damage DNA, proteins, and lipids, free radicals are
believed to play a key role in the onset and progression of late-diabetic complications [57]. In
the absence of an appropriate condensation by antioxidant defense network, increased
oxidative stress leads to activation of stress-sensitive intracellular signaling pathways and the
formation of gene products that cause cellular damage and contribute to late diabetic compli‐
cations [58-61].
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Antioxidants and
macromolecules Evidence of oxidative stress Target tissue/organ References
Animals
Enzymatic antioxidants ↓ SOD,CAT,GR, GPX Liver, Pancreas, Liver,kidney [62-64]
Non-enzymatic
antioxidant
↓ Vit E and C Liver, kidney [64]
↓ GSH /GSSG,GSH
Kidney, hippocampus.
Retina,
Heart
[65]
[66]
[67]
[68]
Lipids ↑ TBARS, lipid peroxides, MDA Kidney [69-70]
DNA ↑ 8-OHdG, 8-OHG Plasma, Liver, Kidney [71-72]
Protein ↑ Nitrotyrosine kidneyRetina
[73]
[67]
Reactive oxygen species ↑ ROS Hippocampus [66]
Humans
Enzymatic antioxidants ↑ SOD,CAT, GPX Erythrocyte [74]
Non enzymatic
antioxidants ↓ GSH Erythrocyte [75]
Lipid ↑ F2-Isoprostanes↑ MDA
Urine
Erythrocyte
[76]
[77]
DNA ↑ 8-OHdG Urine [78-79]
Protein ↑ NitrotyrosineProtein carbonyl Plasma [80, 81]
Table 2. Experimental evidence supporting the involvement of oxidative stress
4. Pathways of free radical generation in diabetes mellitus and its
associated complications
In diabetes, ROS is thought to be generated through increased polyol pathway [82], increased
formation of advanced-glycation end products (AGEs) [83] and protein kinase C (PKC)
activation [84].
4.1. Aldose reductase pathway and ROS generation
Aldose reductase is the rate limiting enzyme of the polyol pathway. The nicotinamide ade‐
nine dinucleotide phosphate (NAD(P)H)-requiring aldose reductase, catalyses the reduction
of glucose to sorbitol followed by the oxidation of sorbitol to fructose by NAD+ dependent
sorbitol dehydrogenase. At normal blood glucose concentration (5.5 mM), aldose reductase
catalyzed reaction represents less than 3% of total glucose utilization [85]. However, hypergly‐
cemia results in saturation of hexokinase and more than 30% of glucose is directed into the
polyol pathway [86]. In a diabetic state, polyol pathway increases in tissues that do not require
insulin for cellular glucose uptake, such as retina, kidney, peripheral nerves and blood vessels
[87].
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The overall reaction of the polyol pathway leads to a shortage of intracellular NAD(P)H and
a surplus of NADH, i.e, a reductive imbalance. Increased NADH generation during conversion
of sorbitol to fructose provides substrate for NADH oxidase to generate ROS [88]. NADH
serves as a source of electrons in complex 1 of the electron transport chain resulting in increased
mitochondrial generation of superoxide radical. In diabetic cells, oxidative phosphorylation
in mitochondria is enhanced due to increase flux of electron donors into the electron transport
chain. This drives the inner mitochondrial membrane potential upward causing blockage of
electron transfer inside complex III [89]. Electrons back up to coenzyme Q results and electrons
are transferred one at a time to molecular oxygen, generating superoxide. DNA damage by
superoxide and peroxynitrite results in the activation of poly (ADP-ribose) polymerase
(PARP), a DNA repair enzyme. PARP reduces the activity of glyceraldehyde-3- phosphate
dehydrogenase (GAPDH) (an enzyme of the glycolytic pathway which catalyses the conver‐
sion of glyceraldehydes -3 phosphate to 1, 3 biphosphoglycerate) by ADP- ribosylation [90,
91]. A consequence of GAPDH inhibition by PARP is an increase in triose phosphate pool,
upstream of GAPDH and increase flux of intermediates into the damaging pathways of
diabetic complications.
The polyol pathway also results in reduction in the bioavailability of NAD(P)H. The reduced
bioavailability of NAD(P)H negatively affects the antioxidant defence system by depleting
glutathione (GSH) a very important antioxidant. This is because the activity of GSH reductase,
an antioxidant enzyme that generates GSH from its oxidized form (GSSH) depends on
NAD(P)H. Depletion of NAD(P)H also decreases the synthesis of nitric oxide (NO), a vaculo‐
protective agent. NAD(P)H serves as a cofactor for nitric oxide synthase (NOS) which
synthesizes NO from L-arginine. If endothelial nitric oxide synthase (eNOS) lack its substrate,
L-arginine or one of its co-factor, it may produce superoxide radical (.O2 -) instead of NO and
this is referred to as ‘‘uncoupled state of nitric oxide’’[92]. Nitric oxide performs several
physiological roles such as inhibition of platelet activation, vascular relaxation [93] and acts
as an anti-inflammatory agent by reducing platelet aggregation and adhesion [94]. These
properties inhibit atherogenesis and protect the blood vessel. Reduced bioavailability of NO
level will therefore increase inflammation, enhance thrombosis and disrupt the integrity of
endothelial cells. Reduction in NO has been documented in diabetes subjects with nephrop‐
athy [95]. Superoxide anion directly quenches NO by forming highly reactive peroxynitrite
(ONOO-) which initiates lipid peroxidation, oxidizes sulfhydryl group in protein and nitrates
amino acids such as tyrosine, thereby affecting many signal transduction pathways. The polyol
pathway serves as a main source of ROS generation in the retina [96]. In addition, sorbitol
accumulation has been implicated in osmotic swelling of the eye lens and cataractogenesis [97].
4.2. Advanced glycation end product (AGEs) formation and ROS generation in diabetic
complications
Glucose can react spontaneously with free amino groups of protein to form Schiff bases. These
Schiff bases through complex reactions such as amadori rearrangement, dehydration and
condensation forms cross-linked heterogeneous fluorescent derivatives called advanced
glycation end products (AGEs). Advanced glycation end products constitute a heterogeneous
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group of molecules formed by non-enzymatic reactions of reducing sugars, ascorbate and
other carbohydrates with amino acids, lipids and nucleic acids [98, 99]. Glycation end product’s
adducts such as pyraline, pentosidine and N- Carboxy- methyl lysine (CML) are found to be
elevated in diabetic tissues [100 - 102].
Once formed, AGEs can cause tissue damage by two main pathways which are: (1) formation
of cross links that alter protein structure and function and, (2) interaction of AGE with AGE-
cell surface receptors on the surfaces of various cells such as endothelial cells, macrophages,
neurons, and smooth-muscle cells resulting in activation of cell signaling and gene expression
that induces oxidative stress and inflammation [98, 99; 102-105]. Oxidative stress can accelerate
AGE formation while AGE formation can also amplify the production of more ROS resulting
in a vicious cycle of AGE formation and oxidative stress.
AGE’s mediate some of their effect via interaction with some receptors that have been shown
to bind to these chemical moieties. Among these receptors, Receptor for Advanced Glycation
End products (RAGE) is the most extensively studied [106]. Evidence from numerous studies
suggest that AGE’s are involved in a vicious cycle of inflammation, generation of ROS and
increased production of AGE’s. Ligand RAGE interaction results in activation of pathways
such as p21ras, erk1/2 (p44/p42), MAP kinases, p38 and SAPK/JNK MAP kinases [107-109]. A
consequence of the activation of these pathways is the nuclear translocation of transcription
factor, Nuclear Factor Kappa B (NF-КB). Translocation of NF-КB to the nucleus increases the
transcription of a number of proteins such as, vascular endothelial growth factor (VEGF),
monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1)
and intracellular adhesion molecule-1 (ICAM-1) and pro-inflammatory cytokines such as
interleukin (IL)-1β, IL-6, 1L-18 and tumour necrosis factor (TNF)-α which are centrally
involved in the endothelial recruitment of neutrophil and subsequent development or
progression of atherosclerotic plaque [109-112].
The gene regions of NF-КB are located at the promoter region of RAGE. Moreover, binding of
NF-КB to the promoter region of RAGE results in up-regulation of RAGE itsel. Interaction of
AGE with RAGE generates more oxidative stress and this further potentiates the formation of
AGE’s [109, 113]. Generation of ROS by ligand stimulated RAGE activation is mediated at least
in part via activation of NADPH oxidase [114]. Other mechanisms by which AGE’s may be
linked to increased generation of ROS is by reducing the activities of enzymatic antioxidant
such as SOD and CAT, lowering of glutathione stores, and activation of PKC [107, 115, 116].
Increased renal AGE in diabetic animals and patients have been linked to structural abnor‐
mality observed in diabetic nephropathy such as mesangial expansion, glomerular basement
membrane thickening and tubulointerstitial fibrosis [117]. Advanced Glycation End Product’s
level is increased with decreased renal function in type 1 diabetic patients [118]. Evidence from
clinical studies indicates a correlation between progression of diabetic retinopathy and the
level of AGE in serum and retinal blood vessels of diabetic patients [100, 119]. In diabetes,
increased AGE’s are observed within retinal capillary cells and causes pericyte loss in diabetic
retinopathy [120]. AGE’s induce toxic effects on retinal pericytes by causing oxidative stress
and subsequent apoptosis [121].
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High levels of serum AGE’s have been documented in patients with type 2 diabetes mellitus
and coronary heart disease [122]. Glycation increases susceptibility of low density lipoprotein
(LDL) to oxidative modification which is considered a critical step in its atherogenicity [123].
Glycation end products can also enhance atherosclerosis by trapping LDL in the subendothe‐
lium and decrease the recognition of AGE-modified LDL by LDL receptor [124]. Modification
of LDL and its increased localization in vessels increases foam cell production and accelerates
atherosclerosis development [125]. Oxidative stress induces AGE’s formation on collagen
leading to cross-linking which is considered to play a role in diabetic cardiomyopathy [126].
The intermolecular collagen cross-linking caused by AGE increases vascular stiffness and
interferes with arterial blood flow [127, 128] and this partly explains the diastolic dysfunction
and systolic hypertension seen in diabetic subjects.
4.3. Protein kinase C (PKC) activation and ROS generation in diabetic complications
PKC activation is related to vasoconstriction, proliferation and overgrowth of smooth muscle
cells as well as accelerated synthesis of extracellular matrix proteins, and thus plays significant
roles in the onset and progression of vascular cell dysfunction in diabetes mellitus [129-131].
Two major pathways have been implicated in the activation of PKC in hyperglycemia.
Persistent and excessive activation of several PKC isoforms result primarily from enhanced
de novo synthesis of diacylglycerol (DAG) from glucose via increase in triose phosphate
availability [90, 105, 132, 133]. There is also evidence that the interaction between AGE’s and
their cell-surface receptors can result in enhanced activity of PKC isoforms [134, 135].
PKC likely regulates diabetic complications on multiple levels such as activation of eNOS,
NAD(P)H oxidase, phospholipase A2 (PLA2), endothelin-1 (ET-1), Vascular endothelial growth
factor (VEGF), Transforming growth factor-β (TGF-β), and by activating NF-KB. Diacylgly‐
cerol activated PKC alters the gene expression of key proteins leading to decrease blood flow,
capillary occlusion, inflammation, free radicals generation and damage to cellular macromo‐
lecule [130-132, 136, 137].
High glucose levels can stimulate ROS production via a PKC-dependent activation of
NAD(P)H oxidase in cultured aortic endothelial cells, smooth muscle cells, and renal mesan‐
gial cells [84]. Nicotinamide adenine dinucleotide phosphate oxidase, which is primarily found
in phagocytic cells, is the main source of ROS in non-phagocytic cells such as mesangial cells,
endothelial cells [138], fibroblasts [139], podocytes [140] and smooth muscle cells [141]. The
expression of NAD(P)H oxidase components is up-regulated in vascular tissues from animal
models of diabetes and in patients with diabetes and coronary artery disease [142-144].
Experimental evidence indicates that NAD(P)H oxidase-dependent production of ROS may
cause DNA damage in diabetic renal tissues leading to the development of nephropathy [145].
Increased activity of the NAD(P)H oxidase has also been reported in the retina of diabetic rats
suggesting its involvement in the development of diabetic retinopathy [146].
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5. Antioxidant as therapeutic agents in the management of diabetes
mellitus
Despite efforts to control blood glucose, tissue and organ damage are cumulative over many
years in most diabetic patients. Varying degrees of hyperglycemia are virtually unavoidable
in subjects with diabetes mellitus and glycemic memory has been used to describe the
development of diabetes-related complications in diabetic patients even after normoglycemia
has been restored and initial glycemic environment is remembered in the target organs
[105,147]. It is noteworthy that ROS has been implicated as a major cause of the metabolic
memory after glucose normalization due to the chains of reactions leading to cell damage and
loss of cellular function. Due to the implication of hyperglycemia-induced oxidative stress in
diabetes, these patients should in theory benefit from antioxidant supplementation. The
beneficial effect of antioxidants has been reported in animal models of diabetes and in diabetic
patients [50, 148]
6. Vitamins
Vitamin E is a fat-soluble vitamin. It has been shown that plasma α-tocopherol concentrations
are lower in diabetics compared to controls [58] and appear to be even lower in diabetics with
complications such as microangiopathy than in diabetics without complications [81]. Admin‐
istration of Vitamin E has proven to be beneficial in preventing cellular damage by inhibition
of lipid peroxidation, protein oxidation, protein glycations and platelet aggregation [149-151]
Vitamin E supplementation for two weeks (600 mg/day) lowered urinary F2-isoprostanes (a
marker of lipid oxidation) in type 2 diabetics [152]. It was shown in a study that a decrease in
plasma F2-isoprostanes was seen in type 2 diabetic patients after six weeks supplementation
with Vitamin E [153].
Oxidative stress in the kidney of diabetics is usually associated with tissue damage that
interferes with proper organ function, causing an increase in urinary protein excretion and
blood urea nitrogen (BUN) [154]. Vitamin E supplementation (1000 IU/kg diet) to diabetic rats
for 4 weeks significantly reduced urinary protein excretion and BUN suggesting a beneficial
effect on kidney function [154]. Inhibitory effect of Vitamin E on glycation of hemoglobin in
type I and type 2 diabetic rats has been documented [151, 155]. The ability of vitamin E to
inhibit AGE’s might be due to its antioxidant effect on the autoxidative pathways of AGE
formation [156]. Vitamin E administration has also reduced oxidation of low density lipopro‐
tein (LDL) and development of atherosclerosis [157].
Numerous studies have shown that vitamin E normalized parameters of oxidative stress and
inhibited vascular abnormalities caused by hyperglycemia-induced production of DAG and
PKC activation in the retina, glomerulus and macrophages [158-160]. Supplementation with
vitamin E reduced basement membrane thickening in diabetic rat retina and reduced vascular
endothelial growth factor (VEGF) and aldose reductase activity, the abnormalities associated
with diabetic retinopathy [161]. Dietary supplementation of vitamin E (2000 IU/kg) to diabetic
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rats for 8 weeks had cardioprotective effects which was simultaneously associated with an
ability of vitamin E to blunt diabetes-induced amplification of myocardial 8-iso PGF2 and
oxidized GSSG formation [162]. Clinical trials with vitamin E provided evidence that vitamin
E may improve cardiovascular function [163, 164]. However, most large studies with vitamin
E have not yielded positive benefits for decreasing the development or progression of diabetic
microvascular and cardiovascular pathologies or mortality [165, 166].
Vitamin C is an antioxidant vitamin which plays an important role in protecting free radical-
induced damage and a decrease in basal vitamin C levels has been documented in type 2 DM.
Treatment of diabetic rats with vitamin C significantly decreased renal malondialdehyde,
albuminuria, proteinuria, glomerular and tubulointerstitial sclerosis, suggesting the role of
vitamin C in suppressing the progression of renal injury in diabetic rats [167]. Vitamin C also
improved diabetes-induced endothelial dysfunction in a rat model by enhancing NO bioa‐
vailability [168].
The beneficial effects of vitamin C supplementation in humans are controversial. A study
reported that vitamin C may improve glycemic control, lowering both fasting blood glucose
and glycated haemoglobin (HbA1c) [169]. Chronic oral administration of vitamin C to patients
with type 2 diabetes causes a decline in plasma free radicals that is associated with improved
whole body glucose disposal [170,171] and improved endothelial function [172]. Recently,
another study reported a reduction in the malondialdehyde (MDA) level, a major product of
oxidative damage in both fasting and postprandial states of type 2 diabetic patients after
vitamin C (1000 mg day-1) supplementation for 6 weeks although no effect was observed on
lipid profiles [173]. Some studies have indicated that the intra-arterial infusion of vitamin c
restores endothelium-dependent vasodilation in patients with type 1 or type 2 diabetes [174,
175] suggesting that hyperglycemia-induced oxidative stress mediates endothelial dysfunc‐
tion in diabetic patients.
However, in contrast to these promising results, other studies showed no beneficial effect with
vitamin C treatment. Chen and colleagues [176] concluded that a high oral dose of vitamin C
therapy was ineffective at improving endothelial dysfunction and insulin resistance in type 2
DM. It is important to note that complete replenishment of vitamin C levels was not achieved
in the subjects. This is crucial since high concentrations of vitamin C (>80 μM) has been
documented as a requirement for the preservation of NO-dependent endothelial function as
vitamin C only competes with NO for superoxide anion at these high concentrations [177-178].
Also, in another study, no beneficial effects of oral vitamin C supplementation (1.5 g daily for
3 weeks) was observed on blood pressure, oxidative stress, and endothelial function in type 2
diabetes [179].
7. Flavonoids
Flavonoids (bioflavonoids) are a diverse group of polyphenols (phenyl benzopyrans) which
function as phytochemicals [180]. Flavonoids are well-known for their multi-directional
biological activities including anti-diabetic efficacy. Experimental evidence has shown that
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flavonoids exhibits anti-inflammatory [181], anticarcinogenic [182], antiviral [183] and
antiallergic properties. These effects are generally associated with free radical scavenging
activity of flavonoids. The antioxidant effects of flavonoids are enhanced by the number and
position of hydroxyl groups in the molecule. The catechol structure, presence of unsaturation
and 4-oxo function in the C-ring also contributes to their radical scavenging activity [184,
185]. Flavonoids may be capable of binding the transition metal ions, which play a role in
glycoxidation, thus preventing metal-catalysed formation of hydroxyl radicals or related
species from H2O2 [186].
Flavone    Flavonol      Flavanone 
 
  
Isoflavone      Flavan-3-ols 
 
Figure 1. Classes of flavonoids [187]
The potential beneficial effects of flavonoids in the prevention of diabetes mellitus and its
associated complications have been investigated both in vitro and in vivo studies (Table 3). The
inhibitory effect of flavonoids on glycation has been demonstrated and it is suggested that this
effect is partly due to their antioxidant properties [188]. Epigallocatechin (EGC) has a beneficial
effect in a rat model of diabetic nephropathy via suppressing hyperglycemia, proteinuria and
lipid peroxidation. EGC also reduced renal accumulation of AGE’s and their related oxidative
stress [189]. Another study demonstrated the in vitro inhibitory effect of different flavonoids
on pentosidine formation in collagen in the presence of glucose (250 mmol/L). The decreasing
inhibitiory activity was observed from myricetin, quercetin, rutin, catechin and kaempferol in
a structure and concentration dependent manner [190]. Kim and colleagues [191] also inves‐
tigated the effect of quercetin, isoquercitrin, hyperin and cacticin on formation of AGE’s in
vitro. At a concentration of 50 mΜ, the percentages of inhibition were 1.0, 89.6, 92.0 and 40.5,
respectively. The inhibitory effect of hyperin on AGE formation was 6.5 times higher than that
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of aminoguanidine, a known AGE inhibitor which showed 14.1% inhibition at a concentration
of 50 μM.
Flavonoids, in addition to their antioxidant effect, possess inhibitory activity on aldose
reductase pathway and can serve as a potential multifunctional agent in the prevention of
diabetic retinopathy. Goodarzi et al. [192] showed that oral administration of quercetin and
the flavanone, naringin to streptozotocin-induced diabetic rats significantly reduced aldose
reductase activity in the lenses compared to control. Oral administration of two isoflavone
compounds, tectorigenin and irigenin also inhibited sorbitol accumulation in the lenses of
streptozotocin induced diabetic rats [193].
Activation of PKC contributes to the loss of capillary pericytes and thickening of vascular
basement membrane (BM) in diabetic retinopathy [194]. Also PKC mediated alterations in
vascular permeability, blood flow, formation and response to angiogenic growth factors
contribute to retinal leakage, ischemia, and neovascularisation [195]. Therefore, PKC inhibitors
can be targeted for the treatment of diabetic retinopathy. Hesperetin (Hsp), a flavanone found
in citrus fruits and a potent antioxidant has retina vasculo-protective properties due to its
strong anti-angiogenic effect via inhibiting VEGF and PKC-β pathways [196]. Modulation of
endogenous biomarkers and inhibition of diabetes induced neuropathic pain was observed in
diabetic rats after naringin (4′,5,7-trihydroxy flavonone 7-rhamnoglucoside) administration
[197]. In the same study, a dose dependent decrease in the levels of oxidative-nitrosative stress,
inflammatory mediators as well as apoptosis was documented in neural cells. The antioxidant
properties of naringin may be a factor in the inhibition of neurodegeneration.
The soy isoflavone genistein (3 and 6mg/kg), administered by a subcutaneous injection to
diabetic mice relieved peripheral painful neuropathy by reverting the proinflammatory
cytokine and ROS overproduction. It also restored the inducible nitric oxide synthase (iNOS)
and eNOS content and increased NO production in thoracic aorta although treatment had no
effect on hyperglycemia [198]. The flavonoid luteolin (200 mg/kg), when administered to rats
orally, protected against the progression of diabetes-induced cardiac dysfunction by attenua‐
tion of myocardial oxidative stress probably through its antioxidant properties [199].
In a double blind placebo-controlled study, the effects of daflon 500 (made up of flavonoids
diosmin (90%) and hesperidin (10%)) was investigated in a group of 28 type 1 diabetic patients.
Treatment with these flavonoids resulted in a decrease in HbA1C which is associated with an
increase in the level and activities of thiol-containing antioxidants such as glutathione
peroxidase [200]. The in vitro protective effect of myricetin on protein oxidation and membrane
lipid peroxidation of erythrocytes from diabetic patients was reported in a study by Pandey
and co-workers [201].
The treatment of diabetic rats with rutin decreased fasting plasma glucose, glycosylated
haemoglobin, thiobarbituric acid reactive substances and lipid hydroperoxides while levels of
non-enzymatic antioxidants were increased [202]. In another study, rutin supplementation
(500 mg tablets) to diabetic patients for 60 days decreased the levels of fasting blood glucose,
blood pressure and improved lipid profiles in the diabetic subjects [203]. Rutin reduced blood
glucose, ameliorated oxidative stress and inhibited the accumulation of extracellular matrix
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(ECM) component and glomerular basement membrane thickening in the renal cortex of
diabetic rats suggesting its renoprotective effect in experimental diabetic nephropathy [204].
The inhibitory effect of rutin on AGE formation in STZ-induced rats has also been shown [205].
Diosmin (DS) (diosmetin 7-O-rutinoside) is a natural flavone glycoside which can be obtained
by dehydrogenation of the corresponding flavanone glycoside, hesperidin that is abundant in
the pericarp of various citrus fruits [206]. Diosmin treatment of streptozotocin-nicotinamide
induced diabetic rats, ameliorated oxidative stress in plasma and tissues as evidenced by
improved glycemic and antioxidant status along with decreased lipid peroxidation [207].
Experimental evidence showed the potential of rutin, a flavonol to delay glomerulosclerosis
of diabetic nephropathy (DN) due to its ability to inhibit cell hypertrophy and the accumulation
of ECM mediated by TGF-β1/Smads and ROS signals in mesangial cells cultured by high
glucose [208] Quercetin enhances endothelium-derived NO bioavailability, reduced blood
glucose levels and oxidative stress in diabetic rats suggesting its beneficial effect in vascular
function [209].
Classes of
Flavonoid and
Food sources
Selected
examples
Target organ,
tissue or cells Mechanism of action Reference
Flavonols
(Brussel sprouts,
apples, onion,
curly kale, leek,
beans, cherries,
Citrus fruits,
Cranberries)
Morin
Liver
Decreased MDA levels ,
Increased activity of SOD and GSH
concentration.
[210]
Hepatocytes
Decreased ROS production, DNA damage
and apoptosis. Modulation of antioxidant
enzymes; GSH, CAT, SOD and GPX.
[211]
Rutin Kidney, serum,urine
Lowered blood glucose and improved renal
function. Increased total antioxidant
capability activities of SOD, CAT and GPX.
Lowered ECM accumulation and AGE
formation. Decreased renal expression of
TGF-β.
[204]
Quercetin
Pancreas, serum,
erythrocyte.
Lowered MDA and NO level, increased
antioxidant enzyme activity and
preservation of islet cells integrity.
[212]
Kidney , serum,
urine
Lowered blood glucose and improved renal
function. Reduced renal lipid peroxides and
increased activity of anti-oxidative enzymes;
SOD and CAT and non-enzymatic
antioxidant GSH.
[213]
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Classes of
Flavonoid and
Food sources
Selected
examples
Target organ,
tissue or cells Mechanism of action Reference
Flavanones (Citus
peel, Orange juice,
grape fruit juice,
lemon juice)
Hesperidin &
Naringin Liver, serum
Boost antioxidant system by increasing
activities of SOD, GR, GPx, CAT and levels of
non-enzymatic antioxidants; GSH, VIT-C and
VIT-E.
Decreased lipid peroxidation product, MDA
and proinflammatory markers, TNF-α, IL-6.
[214]
Hesperidin Retina, plasma
Decreased aldose reductase activity and
levels of AGE’s, VEGF, ICAM-1, TNF-α, IL-1β
and MDA while increasing SOD activity.
[215]
Naringenin
Pancreas,
heamoglobin,
serum, plasma
Lowered fasting blood glucose, decreased
hyperglycemia, glycated haemoglobin, MDA
and markers of hepatic damage.
Increased levels of insulin and enzymatic
and non-enzymatic antioxidants.
[216]
Kidney, liver
serum, urine,
Improved glycemic control and elevated
insulin level, reduced plasma levels of kidney
dysfunction markers. Lowered renal activity
and expression of NF-KB and pro-
inflammatory cytokine and chemokine,
suppression of PKC activity.
[217]
Flavanolols
(Milk thistle, red
onion,
Siberian larch
tree)
Silymarin Kidney Increased expression and activity of SOD,GPX, CAT. Decreased high blood glucose [218]
Flavones
(Parsley, pepper
celery, broccoli
capsicum)
Luteolin
Kidney
Decreased activity of SOD, MDA content
and expression of Heme Oxygenase-1
(HO-1) protein.
[219]
Aortic ring
Aortic Vasorelaxation, decrease in ROS
production, increased activity of SOD, NOS
and level of NO.
[220]
Diosmin Liver and kidney
Decreased TBARS and hydroperoxides.
Increased activity of enzymatic
antioxidants ;SOD, CAT, GPx, GST and GR
and non-enzymatic antioxidants; GSH,
Vitamin C and Vitamin E.
[207]
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Classes of
Flavonoid and
Food sources
Selected
examples
Target organ,
tissue or cells Mechanism of action Reference
Flavones
Chrysin and
luteolin Serum and aorta
Aortic relaxation, decreased blood pressure,
decreased lipidemia and serum AGE’s.
Increased .NO generation
[221]
Apigenin Serum and liver
Increased insulin levels and decreased
hyperglycemia. Normalized LPO and
endogeneous antioxidants, CAT, SOD, GSH
in the liver.
[222]
Flavan-3-ols (Red
wine and red
grapes, green and
black tea)
Catechin Thoracic aorta
Decreased hyperglycemia NADPH oxidase
activity and ROS production. Increased
insulin level, lowered blood pressure and
improved aortic relaxation.
[223]
Epicatechin
Pancreatic Islets,
plasma,
haemoglobin
Increased anti-inflammatory cytokines,
IL-10, IL-12.
Improved glucose tolerance and insulin
levels and lowered HbA1C.
[224]
Isoflavones
(Soy foods and
legumes)
Genistein Kidney
Decreased MDA level and expression of PKC
and pro-inflammatory proteins such as NF-
KB, MCP-1 and Cox-2.
Activation of antioxidant enzymes and
defense against oxidative damage via
increase expression of Nrf2, a transactivator
of antioxidant genes.
[225]
Daidzein Aorta
Maintenance of endothelium dependent
relaxation and attenuation of oxidative
stress via decrease MDA levels and increase
SOD activity
[226]
Abbreviations: Find all citations in this journal (defECM: Extracellular matrix, MDA: Malondialdehyde, NO: Nitric oxide,
NOS: Nitric oxide synthase, NADPH; nicotinamide adenine dinucleotide phosphate, LPO: Lipid peroxidation, Nrf2: NF-
E2-related factor-2, Cox-2: Cyclooxygenase-2, TAOC: Total antioxidative capability
Table 3. Beneficial effects of some flavonoids in diabetes mellitus
The inherent antioxidative properties of some common antidiabetic drugs such as aminogua‐
nidine, statins, thiazolidinediones, glibenclamide and repaglinide also provides an additional
support to the involvement of oxidative stress in diabetes and therefore suggest that the use
of antioxidants as therapeutic agents in diabetes is a promising approach [227-231].
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8. Conclusion and future perspective
Increased ROS production has been suggested as a common pathway linking diverse patho‐
genic mechanisms of diabetic vascular complications. There are numerous evidences from
animal studies on the beneficial effect of antioxidant vitamins supplementation in diabetes
mellitus, but results from clinical studies are inconclusive. The antioxidant activity of some
anti-diabetic drugs has also been shown to contribute significantly to their therapeutic effect.
Biflavonoids as antioxidants are promising and attractive natural substances to enrich the
current therapy options against diabetes. The overall positive results from animal studies
suggest that the role of antioxidants cannot be underestimated in the quest to find effective
therapies for diabetic complications. A multi-therapeutic approach to the treatment of diabetic
complications might increase the chance of successful therapeutic intervention. In addition to
maintaining glycemic control, blockage of pathways involved in the formation of free radicals
with antioxidants is a promising approach to the treatment of hyperglycemia-mediated
complications in humans. The bioactivity of flavonoids in vivo can be greatly influenced by
metabolism and bioavailability and this information is limited in many studies. Limited clinical
studies have been carried out to support the beneficial effects of flavonoids in the prevention
of diabetic complications. In order to achieve the goal of using flavonoids in the management
of diabetes mellitus, further investigation on the long and short-term effect of the ingestion of
flavonoids in humans is warranted.
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